Cyclo Therapeutics, Inc. a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics’ European Patent Application No.19805439.7 titled, “Methods for Treating Alzheimer’s Disease.” The EPO Communication stated that “[t]he newly filed claims are considered to be allowable” and that “[t]he applicant is therefore requested to bring the description into conformity with these claims.”

N. Scott Fine, CEO of Cyclo Therapeutics, commented, “We continue to execute our strategy designed to bolster our patent estate to protect Trappsol® Cyclo™ for our lead indications in key markets worldwide. This European patent application is an important component of our strategy given the launch of our early onset Alzheimer’s disease clinical development program this year.”

Source:cyclotherapeutics.com